Mantle Cell Lymphoma
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Expert Interview
Patients With Newly Diagnosed Mantle Cell Lymphoma and the Relevance of Clinical Trials
Expert Interview
Upfront Transplants in Patients With Mantle Cell Lymphoma
From the Journals
Erythema extent predicts death in cutaneous GVHD
Study: Extent of skin erythema correlates with deaths from graft-versus-host disease in blood cancer patients after stem cell transplants.
News
FDA approves pirtobrutinib for r/r mantle cell lymphoma
Pirtobrutinib for relapsed or refractory mantle cell lymphoma has been approved by the Food and Drug Administration.
Expert Interview
Recent Developments in Mantle Cell Lymphoma: Reflections From ASH 2022
From the Journals
MCL: Event-free survival at 2 years bodes well
With current therapies, patients who achieve 24 months of event-free survival live almost as long as the general population.
Conference Coverage
MCL: Ibrutinib could become the ‘new standard’
New research showed ibrutinib outperformed HSCT for treating younger patients with mantle cell lymphoma.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...